Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP3 | P15309 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.36 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.36 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5065151 | 0.85 | KDM4E (0.55) | KDM4EALDH1A1GAAAOC3LMNA | |
| SCHEMBL5065158 | 0.85 | KDM4E (0.55) | KDM4EALDH1A1GAAAOC3LMNA | |
| SCHEMBL14908702 | 0.85 | KDM4E (0.55) | KDM4EALDH1A1GAAAOC3LMNA | |
| SCHEMBL836485 | 0.82 | AOC3 (0.46) | AOC3NPY5RTRPM8GPR139 | |
| SCHEMBL836486 | 0.82 | AOC3 (0.46) | AOC3NPY5RTRPM8GPR139 | |
| SCHEMBL20492448 | 0.82 | ALDH1A1 (0.40) | KDM4EALDH1A1GAAAOC3LMNA | |
| SCHEMBL17603852 | 0.79 | ACP3 (0.39) | ACP3ALDH1A1AOC3CYP26A1ABCB1 | |
| SCHEMBL835711 | 0.79 | UGT2B7 (0.49) | AOC3HIF1A | |
| SCHEMBL7647994 | 0.76 | NPY5R (0.46) | KDM4EALDH1A1GAAAOC3LMNA | |
| SCHEMBL4934441 | 0.75 | OPRM1 (0.37) | ACP3KDM4EALDH1A1AOC3CYP26A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143290-B2 | Chemical compounds 572 | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| US-20110071194-A1 | Chemical Compounds 572 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071194-A1 | Chemical Compounds 572 | ABCG2, ABCB1, CYP11B2 | ACP3 1240/4885KDM4E 2848/4885ALDH1A1 699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.